Superpower

Live better. A new health system to extend and enhance human life.

[Superpower @superpower]

BREAKING: Retatrutide more than doubled the weight loss of Ozempic in a head-to-head Phase 3 trial.

[Max Marchione @maxmarchione]

Retatrutide led to more than double the weight loss of Ozempic in a head-to-head Phase 3 trial of people with type 2 diabetes.

- 20.9% bodyweight lost on 12mg vs. 9.4% on Ozempic 2mg (its highest dose)

- 47.4 pounds on avg. vs. 20.9

2027 is the year of retatrutide.

[Max Marchione @maxmarchione]

BREAKING: HHS just released a policy which makes 6 peptides accessible through compounding pharmacies (with a prescription).

We’re talking about BPC-157, TB-500, MOTS-c, Semax, Epitalon and KPV, which have mostly been available through the gray market.

The peptide era is here.

[Superpower @superpower]

Source:
https://t.co/T1bEtdH2gh

[Superpower @superpower]

BREAKING: The White House has just finished reviewing the FDA's new peptide compounding policy, clearing the way for the FDA to issue it.

[Superpower @superpower]

Source:
https://t.co/JBixZ4Vlmw

[Superpower @superpower]

BREAKING: For the first time, a therapy designed to reverse the age of cells has been tested in humans.

2 of the first 3 patients improved on their vision tests.

[Superpower @superpower]

We're thrilled to announce the Superpower Peptide Library.

Every peptide, mapped to the body.

152 peptides, from approved drugs to compounds still in trials, sorted by where they act.

Each one has its own page, reviewed by a physician and fully cited, covering:

- the evidence and how strong it is
- its FDA status
- it's mechanism of action
- what studies in humans have found

Because not all peptides are equal.

Semaglutide is FDA-approved. BPC-157, maybe the most talked-about peptide for recovery and repair, is not. In a 2025 review of its research, 35 of 36 studies were in animals or the lab.

Know the science before you buy the hype.

Check it out here:

https://t.co/XXDKz3dk6M

[Superpower @superpower]

Our Superpower Concierge team is best positioned to handle your questions to ensure you get the most accurate, secure, and personalized support.

You can reach Superpower Concierge primarily via text (SMS) or email:
◦ Text (SMS): [phone]⁠⁠
◦ Email: [email protected]

[Superpower @superpower]

We're thrilled to announce the Superpower Peptide Library.

Every peptide, mapped to the body.

152 peptides, from approved drugs to compounds still in trials, sorted by where they act.

Each one has its own page, reviewed by a physician and fully cited, covering:

- the evidence and how strong it is
- its FDA status
- it's mechanism of action
- what studies in humans have found

Because not all peptides are equal.

Semaglutide is FDA-approved. BPC-157, maybe the most talked-about peptide for recovery and repair, is not. In a 2025 review of its research, 35 of 36 studies were in animals or the lab.

Know the science before you buy the hype.

Check it out here:

https://t.co/XXDKz3dk6M

[Superpower @superpower]

@Mathg13 Our care team is here for you. You can reach the Superpower Care Team via email at [email protected] or via text (SMS) at [phone].

[Superpower @superpower]

Watch here: https://t.co/sItmFFpuvn

[Superpower @superpower]

The most dangerous plaque isn't what you think.

In a study of 697 people who had just been through a serious heart event, the untreated spots that caused the next one were only about a third narrowed, on average.

Watch the full video in the link below.

[Max Marchione @maxmarchione]

Superpower peptides are coming soon.

99% purity, US compounded, held to a new standard. Blown away by the response to our Peptide Library.

Join the waitlist:

https://t.co/nTGmxCQN9y

[Superpower @superpower]

Read more: https://t.co/mwm3vDiPjw

[Superpower @superpower]

BREAKING: Endometrial cancer drug could change clinical practice.

The drug adds nearly 7 months of survival and cuts the risk of death by 32%.

Now under FDA priority review.

[Superpower @superpower]

Sources:

https://t.co/m4eUtNJamh

https://t.co/Uz4jnvGPUb

[Superpower @superpower]

In a Phase 3 trial, a daily peptide injection made hepatitis D undetectable in half of patients after about three years.

It’s the first FDA-approved treatment for the disease, and it’s modeled on a piece of hepatitis B.

Here’s the breakdown: (1/13)

[Superpower @superpower]

Bulevirtide shows what’s possible when researchers know exactly how a virus gets into cells. Instead of attacking hepatitis D directly, it blocks the receptor the virus depends on.

The same approach could apply to other viruses that rely on one main way in.